Azacitidine Clinical Trials
93 recruitingDrug
Phase 254Phase 141Phase 39Not Applicable3Phase 41Early Phase 11
Showing 1–20 of 93 trials
Recruiting
Phase 2
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+2 more
National Cancer Institute (NCI)2,000 enrolled348 locationsNCT05564390
Recruiting
Phase 2
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center45 enrolled7 locationsNCT07392242
Recruiting
Phase 2
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia
National Cancer Institute (NCI)147 enrolled227 locationsNCT06317649
Recruiting
Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia
National Cancer Institute (NCI)153 enrolled178 locationsNCT05554393
Recruiting
Phase 2
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Acute Myeloid LeukemiaAcute Myeloid Leukemia Post Cytotoxic TherapyAcute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm+1 more
National Cancer Institute (NCI)335 enrolled222 locationsNCT05554406
Recruiting
Phase 1
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
Acute Myeloid LeukemiaMyelodysplastic Syndrome
City of Hope Medical Center43 enrolled1 locationNCT06498973
Recruiting
Phase 1
FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia
Acute Myeloid Leukemia
Fred Hutchinson Cancer Center9 enrolled1 locationNCT07645469
Recruiting
Phase 1Phase 2
A Study of BGB-11417 in Participants With Myeloid Malignancies
Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasm
BeOne Medicines260 enrolled46 locationsNCT04771130
Recruiting
Phase 2
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
Acute Myeloid Leukemia
Joshua Zeidner53 enrolled7 locationsNCT05442216
Recruiting
Phase 1Phase 2
Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse
Leukemia, Myeloid, Acute
Zhujiang Hospital40 enrolled1 locationNCT05270200
Recruiting
Phase 2
Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms
Myeloproliferative Neoplasm
University Health Network, Toronto40 enrolled1 locationNCT05074355
Recruiting
Phase 1
Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
Acute Myeloid Leukemia
OHSU Knight Cancer Institute40 enrolled1 locationNCT07548983
Recruiting
Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome+2 more
Jennifer Saultz51 enrolled3 locationsNCT03874052
Recruiting
Phase 2
Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
Acute Myeloid Leukemia
University of California, Davis28 enrolled1 locationNCT07304011
Recruiting
Phase 1
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
Acute Myeloid LeukemiaMyelodysplastic Syndrome/Acute Myeloid Leukemia
OHSU Knight Cancer Institute30 enrolled1 locationNCT06357182
Recruiting
Phase 1Phase 2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Acute Myeloid LeukemiaNon-Hodgkin LymphomaMultiple Myeloma+3 more
CellCentric Ltd.250 enrolled39 locationsNCT04068597
Recruiting
Phase 2
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Acute Myeloid Leukemia
Alice Mims125 enrolled4 locationsNCT05401097
Recruiting
Phase 2
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
Breast Cancer InvasiveHigh Risk Breast CarcinomaEarly Stage Breast Cancer
University of Illinois at Chicago40 enrolled1 locationNCT04891068
Recruiting
Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Acute Myeloid LeukemiaMyelodysplastic SyndromeBlastic Plasmacytoid Dendritic Cell Neoplasm
Dana-Farber Cancer Institute72 enrolled3 locationsNCT03113643
Recruiting
Phase 1
A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
Acute Myeloid Leukemia
M.D. Anderson Cancer Center32 enrolled2 locationsNCT05834244